GET DAILY SIGNALSSurgery Partners (SGRY) Approaches the $23.50 Acquisition Price
Key Takeaways
- Surgery Partners, Inc. (SGRY) is a healthcare services company that operates ambulatory surgery centers (ASCs), surgical hospitals, and physician partnerships across more than 200 locations in 30 states.
- The central $23.50 target used here is the all-cash merger consideration agreed to with HealthSpan Partners, not an average of analyst price targets; the stock is being taken private at $23.50 per share in cash.
- With shares trading near $23.20, the gap to $23.50 is only about 1.3% — a deal-discount gap reflecting time and closing risk, not a growth-driven move.
- Analyst price targets have converged around the deal price, with a recent range of roughly $19 to $24.70 and an average near $22, well below the 10% threshold a typical upside target would require.
- The strongest supporting factors are the signed definitive agreement, secured financing, and a voting agreement in which Bain Capital (about 39% owner) agreed to vote in favor.
- The biggest risks are shareholder approval, regulatory clearance, deal-termination or litigation risk, and the possibility that a competing bid emerges at a higher price.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the additional pages available for SGRY.
- You can also explore Trending AI Robots to see how AI-driven tools are scanning the market for opportunities.
Analyst Price Targets and Consensus View
SGRY does not fit the standard "average analyst price target" framework because of a fundamental change in its corporate situation. On October 26, 2026, Surgery Partners announced a definitive agreement under which HealthSpan Partners — an affiliate of Bon Secours Mercy Health — would acquire the company in an all-cash transaction valued at approximately $5.7 billion in enterprise value. Shareholders would receive $23.50 per share in cash, with Bain Capital rolling over its equity rather than being cashed out.
Because a binding cash offer now effectively caps the stock's value, sell-side price targets have collapsed toward the merger price. Recent targets range from roughly $19 to $24.70, with a mean near $22 — in many cases at or below the current share price. This is presented strictly as context: no credible analyst target sits 10% or more above the current price, because the announced deal price is $23.50. Post-announcement, several firms downgraded their ratings to Hold or Neutral, including StoneX and UBS in late October 2026, while others, including Cantor Fitzgerald and RBC Capital, adjusted targets to $24. The $23.50 figure is therefore a deal price, not an analyst consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares of SGRY trade near $23.20, just below the $23.50 per-share consideration. Reaching $23.50 requires only about a 1.3% move — a modest gap that reflects the normal discount merger-arbitrage investors apply for the time until closing (expected in the first quarter of 2027) and for the risk that the deal fails to close. This is not a valuation-driven path; it is a matter of whether the transaction completes on its announced terms.
What Could Support a Move Toward the Target
- The merger agreement is definitive and has been unanimously recommended by a special committee of independent directors and approved by the full board.
- HealthSpan Partners intends to fully finance the acquisition through cash on hand and new debt, with commitments already secured.
- Bain Capital, the largest shareholder at roughly 39% of outstanding shares, signed a voting and support agreement to vote its shares in favor of the deal.
- Financial advisors, including Centerview Partners, Leerink Partners, and Moelis & Company, delivered fairness opinions on the $23.50 consideration.
What Could Prevent the Target From Being Reached
- The transaction requires approval by a majority of outstanding voting shares and a majority of disinterested stockholders, which is not guaranteed.
- Regulatory approvals and other customary closing conditions must still be satisfied, with closing expected only in the first quarter of 2027.
- Several law firms have announced investigations into whether the $23.50 price is fair to minority shareholders, a common feature of going-private deals that can add delay and litigation risk.
- A competing offer above $23.50, or a deal termination, would alter the picture entirely — potentially moving the price in either direction.
Technical Levels and Market Structure
The deal price of $23.50 acts as a hard ceiling on the stock, which is a meaningful resistance level in its own right. The stock's 52-week high is near $23.44, so the merger consideration sits just above that prior peak. On the downside, an earlier report in late October had valued a potential transaction at $20 per share, and that level, along with the mid-$20s analysts' higher-end targets, frames the zone where shares could settle if deal confidence wavers. Because this is an event-driven situation, traditional support and resistance levels are secondary to deal-progression news. From what I see, this setup makes monitoring news flow especially important.
Time Horizon and What Investors Should Monitor
The relevant horizon here is the expected closing window — the first quarter of 2027 — rather than a typical 12-month research horizon. Investors should monitor the filing and clearance of the proxy statement and Schedule 13E-3, the scheduling and outcome of the shareholder vote, progress on regulatory approvals, any competing bids, and updates to the deal timeline. Each of these milestones, not earnings or guidance, will drive the stock's proximity to $23.50 in the near term. I’m watching this closely as the proxy process unfolds.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot changing trends more efficiently. For an event-driven name like SGRY, such tools can complement deal-progress tracking by flagging shifts in momentum and investor sentiment.
Using AI Tools for Event-Driven Analysis
In my view, AI-driven platforms can help investors stay on top of fast-moving situations like this one. One resource I turn to for additional perspective is Tickeron’s AI Daily Buy/Sell Signals, which provides ongoing signals across a wide range of names and can be particularly useful when tracking merger-related developments alongside traditional news flow.
Final Assessment
The question of whether SGRY can reach $23.50 is less about earnings growth or valuation and more about whether the announced acquisition completes. The $23.50 central target is the all-cash merger consideration, not an analyst-derived price target, and the stock sits only about 1.3% below it. The strongest supports are the binding agreement, secured financing, board and special-committee approval, and Bain Capital's voting commitment; the principal obstacles are shareholder and regulatory approvals, litigation risk, and the possibility of a higher competing bid. Investors should focus on deal milestones rather than fundamental forecasts, and no outcome — including a competing offer or a deal termination — should be assumed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SGRY's Stochastic Oscillator is staying in overbought zone for 17 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SGRY broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on SGRY as a result. In 65 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for SGRY just turned positive on October 12, 2026. Looking at past instances where SGRY's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
SGRY moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SGRY crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
The 50-day moving average for SGRY moved above the 200-day moving average on October 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +0.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where SGRY advanced for three days, in 192 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 120 of 170 cases where SGRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SGRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.818) is normal, around the industry mean (204.532). P/E Ratio (-33.623) is within average values for comparable stocks, (21.572). SGRY's Projected Growth (PEG Ratio) (21.970) is very high in comparison to the industry average of (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.530) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in health care services
Industry HospitalNursingManagement
Advertisement